Molecular Oncology
Volume 2, Issue 4 , Pages 317-326 , December 2008

Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells

  • Juwon Park

      Affiliations

    • Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
    • ,
  • Vasudevan Ayyappan

      Affiliations

    • Department of Biomedical Science, Han Yang University College of Medicine, Seoul, Republic of Korea
    • ,
  • Eun-Kyung Bae

      Affiliations

    • Department of Biomedical Science, Han Yang University College of Medicine, Seoul, Republic of Korea
    • ,
  • Chansu Lee

      Affiliations

    • Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
    • ,
  • Byung-Su Kim

      Affiliations

    • Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
    • Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 28 Yongon-dong, Jongno-gu, Seoul 110-799, Republic of Korea
    • ,
  • Byoung Kook Kim

      Affiliations

    • Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
    • Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 28 Yongon-dong, Jongno-gu, Seoul 110-799, Republic of Korea
    • Clinical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea
    • ,
  • Young-Yiul Lee

      Affiliations

    • Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
    • Department of Internal Medicine, Han Yang University College of Medicine, Seoul, Republic of Korea
    • ,
  • Kwang-Sung Ahn

      Affiliations

    • Department of Pathology, Medical Research Center, Korea University College of Medicine, 126-1 Anam-Dong 5-Ga, Sungbuk-Ku, Seoul 136-705, Republic of Korea
    • Corresponding Author InformationCorresponding author. Tel.: +82 2 920 6371; fax: +82 2 920 3130.
    • ,
  • Sung-Soo Yoon

      Affiliations

    • Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
    • Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 28 Yongon-dong, Jongno-gu, Seoul 110-799, Republic of Korea
    • Clinical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea
    • Corresponding Author InformationCorresponding author. Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 28 Yongon-dong, Jongno-gu, Seoul 110-799, Republic of Korea. Tel.: +82 2 2072 3079; fax: +82 2 762 9662.

Received 11 June 2008 ,Revised 19 September 2008 ,Accepted 22 September 2008.

References 

  1. Anderson KC. Multiple myeloma. advances in disease biology: therapeutic implications. Semin. Hematol. 2001;38:6–10
  2. Barille S, Bataille R, Amiot M. The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma. Eur. Cytokine Netw. 2000;11:546–551
  3. Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood. 2003;101:1053–1062
  4. Blade J, Cibeira MT, Rosinol L. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma. Acta Oncol. 2005;44:440–448
  5. Caers J, Van Valckenborgh E, Menu E, Van Camp B, Vanderkerken K. Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment. Bull. Cancer. 2008;95:301–313
  6. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell. Mol. Life Sci. 2008;65:1631–1652
  7. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat. Rev. Cancer. 2002;2:927–937
  8. Hideshima T, Chauhan D, Hayashi T, Akiyama M, Mitsiades N, Mitsiades C, et al. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene. 2003;22:8386–8393
  9. Kallen KJ. The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim. Biophys. Acta. 2002;1592:323–343
  10. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111:2962–2972
  11. Landis-Piwowar KR, Milacic V, Chen D, Yang H, Zhao Y, Chan TH, et al. The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug Resist. Updat. 2006;9:263–273
  12. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin. Cancer Res. 2003;9:1136–1144
  13. Pagnucco G, Cardinale G, Gervasi F. Targeting multiple myeloma cells and their bone marrow microenvironment. Ann. N. Y. Acad. Sci. 2004;1028:390–399
  14. Podar K, Richardson PG, Hideshima T, Chauhan D, Anderson KC. The malignant clone and the bone-marrow environment. Best Pract. Res. Clin. Haematol. 2007;20:597–612
  15. Popat R, Joel S, Oakervee H, Cavenagh J. Bortezomib for multiple myeloma. Expert Opin. Pharmacother. 2006;7:1337–1346
  16. Sarkar FH, Li Y. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res. 2006;66:3347–3350
  17. Sirohi B, Powles R. Multiple myeloma. Lancet. 2004;363:875–887
  18. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood. 1993;82:3712–3720
  19. Yang HH, Vescio R, Schenkein D, Berenson JR. A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, velcade and melphalan in patients with relapsed or refractory multiple myeloma). Clin. Lymphoma. 2003;4:119–122

PII: S1574-7891(08)00125-7

doi: 10.1016/j.molonc.2008.09.006

Molecular Oncology
Volume 2, Issue 4 , Pages 317-326 , December 2008

Article Tools

* Image Usage & Resolution